Duke Cancer Institute

Research Programs

Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Angeles Secord's Clinical Trials

Jumbo Large Regular Text:

Clinical Trials

Angeles Secord's Clinical Trials

Items 1 - 20 of 23

GOG 0273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Angeles Secord
Phase: N/A
Phone: 919-684-3792

A Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-7471

A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-681-7471

A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen For Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

BMS CA184-201: A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects with Residual Measurable Disease
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-681-7471

GOG #187: Phase II Study of Paclitaxel for Ovarian Stromal Tumors As First-Line or Second-Line Therapy
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0130F: A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in The Treatment of Recurrent or Persistent Carcinosarcoma of The Uterus
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0186-I: A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab with Fosbretabulin Tromethamine (CA4P) (NSC #752293) in The Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0254: A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND# 74019, NSC# 736511) in The Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0260- A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in The Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (Sponsor: GOG, IND# 110072)
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. BLeomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of The Ovary
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0268: A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864, IND# 61010) in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First Line Therapy in The Treatment of Stage III-IV Clear Cell Carcinoma of The Ovary
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-684-3792

Amgen 386: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-684-3792

EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/CAELYX®) in Combination Versus PLD in Participants with Platinum-Resistant Ovarian Cancer
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-684-3792

GOG #0212: Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-684-3792

GOG0241: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #113912) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Subjects with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-684-3792

GOG0250: A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) plus G-CSF with Bevacizumab (NSC #704865, IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) plus G-CSF with Placebo in The Treatment of Recurrent or Advanced Leiomyosarcoma of The Uterus. NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #113912)
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-664-3792

GOG0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-684-3792